Ustun, Celalettin http://orcid.org/0000-0001-6896-6213
Chen, Min
Kim, Soyoung http://orcid.org/0000-0003-1404-0575
Auletta, Jeffery J.
Batista, Marjorie V.
Battiwalla, Minoo
Cerny, Jan
Gowda, Lohith
Hill, Joshua A. http://orcid.org/0000-0002-7665-7100
Liu, Hongtao http://orcid.org/0000-0002-3190-7807
Munshi, Pashna N. http://orcid.org/0000-0002-8079-9443
Nathan, Sunita http://orcid.org/0000-0001-7920-4265
Seftel, Matthew D.
Wingard, John R.
Chemaly, Roy F. http://orcid.org/0000-0002-0277-3088
Dandoy, Christopher E. http://orcid.org/0000-0002-4001-9203
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
Riches, Marcie
Papanicolaou, Genovefa A. http://orcid.org/0000-0002-2891-079X
Article History
Received: 26 April 2023
Revised: 5 October 2023
Accepted: 13 October 2023
First Online: 31 October 2023
Competing interests
: MVB reports compensation (honoraria) from from United Medical, Astra Zeneca, and Merck Sharp Dohme; and research support from National Health Institute- National Cancer Institute (NIH-NCI), National Council for Scientific and Technological Development (CNPq) and FAPESP - Fundação de Amparo à Pesquisa do Estado de São Paulo. MB reports research support (institution) from Novartis. JC reports consulting fees (Advisory Board Membership) for Jazz Pharmaceuticals, Pfizer, and Amgen; Data Safety Monitoring Board member for Allovir Inc.; and stocks with Actinium Pharmaceuticals, Bluebird Bio/2Seventy, Dynavax Technologies, aTyr Pharma, Gamida Cell, Miragen Therapeutics, Mustang Bio, Novavax, Ovid Therapeutics, Sorrento Therapeutics, TG Therapeutics, Vaxart, and Veru. JAH reports compensation (consulting) for Karius; research support from Karius; and significant payments (Scientific Advisory Board) for Karius (limit $10,000). HL reports compensation (advisor/consultant/speaker) for Agios, Pfizer, CTI Biopharm, Nkarta, Servier; research support (funding paid to my institution) for clinical trials from Miltenyi Biotec, Alexion, Astellas, Nkarta, ImmuOnco, Cellularity and Marker. PNM reports Speaker’s Bureau participation for Incyte and Kite; and consultancy for Incyte. JRW reports compensation (consultant) for Cidara, Celgene, Merck, Shire, Orca and Ansun. RFC reports compensation (advisor/consultant/speaker) for Merck, Takeda, Karius, Therapeutics Partners, Ansun, Eurofins-Viracor, Genentech, Qiagen, Oxford Immunotec, Astellas, Roche, Aseptico, AiCuris, and Shinogi; and significant payments (grants and funding paid to my institution for research) from Merck, Ansun, AiCuris, Eurofins-Viracor, Karius, Genentech, Freestyle, and Takeda. MAP reports compensation (honoraria) from Adicet, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Syncopation, VectivBio AG, and Vor Biopharma; Data Safety Monitoring Board participation for Cidara Therapeutics, Medigene, and Sellas Life Sciences; scientific advisory board participation for NexImmune; ownership interests in NexImmune and Omeros; significant payments (honoraria in excess of $5000) from Bristol-Myers Squibb, Incyte, Kite/Gilead, Merck, Nektar Therapeutics, Novartis, Omeros, Cidara Therapeutics (DSMB) and research support (institutional in excess of $5000) for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis; and equity interest in Omeros. MR is an employee of IQVIA Biotech, a clinical research organization. GAP reports compensation (consultant/other) for Allovir, Astellas, Cidara, Merck, Takeda, Therapeutics Partners and Octapharma; and research funding (paid to my institution) from Merck and Takeda.